Japan-based Eisai has received approval from the US Food and Drug Administration (FDA) for antiemetic agent Aloxi (palonosetron HCI) as an additional indication for preventing acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy in children aged from one month up to 17 years.

The company said that despite peak cancer occurances among children occurring within the first year of birth, Aloxiis is the first product for chemotherapy-induced nausea and vomiting (CINV) prevention approved in patients aged between one and six months after birth.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Eisai’s US subsidiary markets the product based on having received exclusive marketing rights from Helsinn Healthcare for the US.

"FDA approval was based on a randomised, double-blind, non-inferiority pivotal trial comparing Aloxi with ondansetron in paediatric patients."

FDA approval was based on a randomised, double-blind, non-inferiority pivotal trial comparing Aloxi with ondansetron in pediatric patients.

The trial’s primary endpoint of complete response was defined as no vomiting, retching or antiemesis rescue medication required within the first 24 hours after chemotherapy. It was achieved in 59.4% of patients who received Aloxi (20mcg/kg, single-dose IV) versus 58.6% of patients who had the ondansetron regimen.

The company said that treatment-emergent adverse events (TEAEs) were comparable across both arms, with the most frequently reported TEAE in the Aloxi group being headaches.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

While the trial showed that pediatric patients require a higher palonosetron dose based on weight than adults to prevent CINV, the safety profile for ALOXI was confirmed as being consistent with the established profile in adults.

In addition, the clinical trial data has met the FDA’s written request requirements for pediatric exclusivity, resulting in an additional six months of US market exclusivity for the drug, which will now expire on 13 October 2015.